Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. trimmed its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 10.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,936 shares of the biopharmaceutical company’s stock after selling 2,067 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Amicus Therapeutics were worth $181,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of FOLD. Janus Henderson Group PLC increased its position in shares of Amicus Therapeutics by 20.1% during the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after acquiring an additional 2,307,385 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Amicus Therapeutics by 583.4% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company’s stock worth $25,640,000 after purchasing an additional 1,858,100 shares in the last quarter. Millennium Management LLC increased its holdings in Amicus Therapeutics by 1,758.9% during the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock worth $18,790,000 after purchasing an additional 1,792,277 shares during the period. William Blair Investment Management LLC raised its position in Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after purchasing an additional 1,477,084 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after buying an additional 1,192,489 shares during the period.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $10,382,718.34. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,401 shares of company stock worth $352,038 in the last quarter. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Trading Down 1.9 %

NASDAQ FOLD opened at $10.49 on Wednesday. The firm’s fifty day moving average is $11.09 and its two-hundred day moving average is $10.61. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.26 and a current ratio of 3.15. The firm has a market cap of $3.13 billion, a PE ratio of -30.85 and a beta of 0.68.

Wall Street Analysts Forecast Growth

FOLD has been the subject of a number of recent research reports. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Cantor Fitzgerald lifted their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Bank of America increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Morgan Stanley cut their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Finally, JPMorgan Chase & Co. upped their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.